Evaluation of a killed feline panleukopenia virus vaccine against canine parvoviral enteritis in dogs.
Immunogenic potency of a killed feline panleukopenia virus vaccine against canine parvoviral enteritis in dogs was examined. The vaccine elicited hemagglutination-inhibition antibodies to canine parvovirus (CPV) in all of the 72 dogs which were vaccinated. The vaccine was protective in dogs against both experimentally induced and naturally occurring CPV-induced disease. By statistical analysis, 4 weeks was found to be the optimal spacing between 2 vaccinal doses resulting in hemagglutination-inhibition antibody titers up to 1:5,120. Adverse reactions to the vaccine were not observed. Atypical lymphocytes were found consistently in the CPV-infected control dogs.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D004751:Enteritis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D028301:Feline Panleukopenia Virus / Q000276:immunology*; D005260:Female; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D006386:Hemagglutination Tests / Q000662:veterinary; D008297:Male; D010321:Parvoviridae / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*
D000914:Antibodies, Viral; D014765:Viral Vaccines